Letrozole Treatment Duration

Introduction to Letrozole Therapy

The American Society of Clinical Oncology recommends letrozole as adjuvant therapy for 5 years in postmenopausal women with hormone receptor-positive breast cancer 1, 3
Extended adjuvant therapy with letrozole for an additional 5 years may be considered for patients at higher risk of recurrence, according to the National Comprehensive Cancer Network 1, 2

The MA.17R trial demonstrated that extending letrozole treatment to 10 years improved disease-free survival compared to 5 years of treatment (95% vs 91%) 1
Multiple trials have evaluated different durations of extended letrozole therapy, with most supporting 5 years as the standard initial duration, as recommended by the American College of Clinical Oncology 2, 4

The National Comprehensive Cancer Network recommends hormone therapy with aromatase inhibitors like letrozole as a treatment option for grade 1 serous/endometrioid and borderline epithelial ovarian carcinoma 5, 6

Extended letrozole therapy is associated with increased risk of bone-related adverse events, including fractures and osteoporosis, as reported by the Journal of Clinical Oncology 7, 8
The American Heart Association notes that cardiovascular events showed a trend toward increased risk with extended AI therapy (odds ratio 1.18) 7
Quality of life assessments during extended letrozole therapy showed worsening in physical role functioning compared to placebo, according to the American Society of Clinical Oncology 1, 2

Regular assessment of bone mineral density is recommended for patients on long-term letrozole therapy, as suggested by the National Osteoporosis Foundation 1, 7
Monitoring for cardiovascular risk factors is important, particularly for extended therapy, according to the American College of Cardiology 7

Standard initial therapy: 5 years of letrozole for hormone receptor-positive breast cancer, as recommended by the American Society of Clinical Oncology 1, 2
Consider extended therapy (additional 5 years) if high risk of recurrence, good tolerance of initial 5 years of therapy, and no significant bone density loss or cardiovascular issues, as suggested by the National Comprehensive Cancer Network 1, 2, 7